LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22 at the Westin New York Grand Central Hotel, and will also present at the 1st Annual H.C. Wainwright NASH Investor Event, taking place April 3, 2017, at the St. Regis Hotel in New York City.
| Oppenheimer & Company 27th Annual Healthcare Conference | ||||||||
| Date: | Tuesday, March 21 | |||||||
| Time: | 3:20pm Eastern Time | |||||||
| Location: | Track 3, Westin New York Grand Central Hotel. | |||||||
| Webcast: | https://www.veracast.com/webcasts/opco/healthcare2017/18113422476.cfm | |||||||
| H.C. Wainwright NASH Investor Event | ||||||||
| Date: | Monday, April 3 | |||||||
| Time: | 9:40am Eastern Time | |||||||
| Location: | Versailles Room, St Regis Hotel, New York City. | |||||||
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has initiated 3 clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH. Please visit www.gemphire.com for more information.